Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Molecular treatments targeting epidermal growth factor receptors (EGFRs) are important strategies for advanced colorectal cancer (CRC). However, clinicopathologic implications of EGFRs and EGFR ligand signaling have not been fully evaluated. We evaluated the expression of EGFR ligands and correlation with their receptors, clinicopathologic factors, and patients’ survival with CRC. Materials and Methods The expression of EGFR ligands, including heparin binding epidermal growth factor–like growth factor (HBEGF), transforming growth factor (TGF), betacellulin, and epidermal growth factor (EGF), were evaluated in 331 consecutive CRC samples using mRNA in situ hybridization (ISH). We also evaluated the expression status of EGFR, human epidermal growth factor receptor 2 (HER2), HER3, and HER4 using immunohistochemistry and/or silver ISH. Results Unlike low incidences of TGF (38.1%), betacellulin (7.9%), and EGF (2.1%), HBEGF expression was noted in 62.2% of CRC samples. However, the expression of each EGFR ligand did not reveal significant correlations with survival. The combined analyses of EGFR ligands and EGFR expression indicated that the ligands/EGFR+ group showed a significant association with the worst disease-free survival (DFS; p=0.018) and overall survival (OS; p=0.005). It was also an independent, unfavorable prognostic factor for DFS (p=0.026) and OS (p=0.007). Additionally, HER4 nuclear expression, regardless of ligand expression, was an independent, favorable prognostic factor for DFS (p=0.034) and OS (p=0.049), by multivariate analysis. Conclusion Ligand-independent EGFR overexpression was suggested to have a significant prognostic impact; thus, the expression status of EGFR ligands, in addition to EGFR, might be necessary for predicting patients' outcome in CRC.
Abstract
Purpose Molecular treatments targeting epidermal growth factor receptors (EGFRs) are important strategies for advanced colorectal cancer (CRC). However, clinicopathologic implications of EGFRs and EGFR ligand signaling have not been fully evaluated. We evaluated the expression of EGFR ligands and correlation with their receptors, clinicopathologic factors, and patients’ survival with CRC. Materials and Methods The expression of EGFR ligands, including heparin binding epidermal growth factor–like growth factor (HBEGF), transforming growth factor (TGF), betacellulin, and epidermal growth factor (EGF), were evaluated in 331 consecutive CRC samples using mRNA in situ hybridization (ISH). We also evaluated the expression status of EGFR, human epidermal growth factor receptor 2 (HER2), HER3, and HER4 using immunohistochemistry and/or silver ISH. Results Unlike low incidences of TGF (38.1%), betacellulin (7.9%), and EGF (2.1%), HBEGF expression was noted in 62.2% of CRC samples. However, the expression of each EGFR ligand did not reveal significant correlations with survival. The combined analyses of EGFR ligands and EGFR expression indicated that the ligands/EGFR+ group showed a significant association with the worst disease-free survival (DFS; p=0.018) and overall survival (OS; p=0.005). It was also an independent, unfavorable prognostic factor for DFS (p=0.026) and OS (p=0.007). Additionally, HER4 nuclear expression, regardless of ligand expression, was an independent, favorable prognostic factor for DFS (p=0.034) and OS (p=0.049), by multivariate analysis. Conclusion Ligand-independent EGFR overexpression was suggested to have a significant prognostic impact; thus, the expression status of EGFR ligands, in addition to EGFR, might be necessary for predicting patients' outcome in CRC.
참고문헌 (29)
- Spano JP, "Impact of EGFR expression on colorectal cancer patient prognosis and survival", Ann Oncol, 16, pp.102~108 (2005)
- Nagahiro Saijo, "Present Status and Problems on Molecular Targeted Therapy of Cancer", Cancer Research and Treatment, 44(1), pp.1~10 (2012), 대한암학회
- 김달용, "Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer", Cancer Research and Treatment, 49(1), pp.37~43 (2017), 대한암학회
- Karapetis CS, "K-ras mutations and benefit from cetuximab in advanced colorectal cancer", N Engl J Med, 359, pp.1757~1765 (2008)
- Schneider MR, "The epidermal growth factor receptor ligands at a glance", J Cell Physiol, 218, pp.460~466 (2009)
- Khambata-Ford S, "Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab", J Clin Oncol, 25, pp.3230~3237 (2007)
- Hobor S, "<TEX>$TGF{\alpha}$<", TEX> and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells, 2014, pp.20, 6429~6438
- Khelwatty S, "The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer", Oncotarget, 8, pp.7666~7677 (2017)
- Ohchi T, "Amphiregulin is a prognostic factor in colorectal cancer", Anticancer Res, 32, pp.2315~2321 (2012)
- Jacobs B, "Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab", J Clin Oncol, 27, pp.5068~5074 (2009)
- Jonker DJ, "Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer", Br J Cancer, 110, pp.648~655 (2014)
- Fujiwara S, "The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer", Oncotarget, 5, pp.3919~3930 (2014)
- Yun S, "Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients", Gastric Cancer, 21, pp.225~236 (2018)
- Wang J, "Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis", Oncotarget, 7, pp.76693~76703 (2016)
- Kyu Sang Lee, "Stromal Expression of MicroRNA-21 in Advanced Colorectal Cancer Patients with Distant Metastases", Journal of Pathology and Translational Medicine, 50(4), pp.270~277 (2016), 대한병리학회[DOI]
- Seo AN, "HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value", Virchows Arch, 466, pp.645~654 (2015)
- Atkins D, "Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections", J Histochem Cytochem, 52, pp.893~901 (2004)
- Chakraborty S, "Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks", Nat Commun, 5, pp.5811~ (2014)
- Guo G, "Ligand-independent EGFR signaling", Cancer Res, 75, pp.3436~3441 (2015)
- Schrevel M, "Autocrine expression of the epidermal growth factor receptor ligand heparin-binding EGF-like growth factor in cervical cancer", Int J Oncol, 50, pp.1947~1954 (2017)
- Iwamoto R, "Characterization of a novel anti-human HB-EGF monoclonal antibody applicable for paraffin-embedded tissues and diagnosis of HB-EGF-related cancers", Monoclon Antib Immunodiagn Immunother, 35, pp.73~82 (2016)
- Zhou ZN, "Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo", Oncogene, 33, pp.3784~3793 (2014)
- Byeon SJ, "Expression of the ERBB family of ligands and receptors in gastric cancer", Pathobiology, 84, pp.210~217 (2017)
- Kawasaki H, "Regulation of intestinal myofibroblasts by KRas-mutated colorectal cancer cells through heparin-binding epidermal growth factor-like growth factor", Oncol Rep, 37, pp.3128~3136 (2017)
- Murata T, "HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers", Cancer Res, 71, pp.6633~6642 (2011)
- Yoshida M, "A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies", J Cancer Res Clin Oncol, 139, pp.367~378 (2013)
- Ito M, "Expression of several growth factors and their receptor genes in human colon carcinomas", Virchows Arch B Cell Pathol Incl Mol Pathol, 59, pp.173~178 (1990)
- Rajagopal S, "Epidermal growth factor expression in human colon and colon carcinomas: anti-sense epidermal growth factor receptor RNA down-regulates the proliferation of human colon cancer cells", Int J Cancer, 62, pp.661~667 (1995)
- Mota JM, "A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer", Oncotarget, 8, pp.89284~89306 (2017)